TY - JOUR
T1 - Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2
AU - Jackson, Sarah A.
AU - Davis, Andrew A.
AU - Li, Jun
AU - Yi, Nengjun
AU - McCormick, Shelley R.
AU - Grant, Carly
AU - Fallen, Taya
AU - Crawford, Beth
AU - Loranger, Kate
AU - Litton, Jennifer
AU - Arun, Banu
AU - Vande Wydeven, Kimberly
AU - Sidani, Amer
AU - Farmer, Katie
AU - Sanders, Merideth
AU - Hoskins, Kent
AU - Nussbaum, Robert
AU - Esserman, Laura
AU - Garber, Judy E.
AU - Kaklamani, Virginia G.
PY - 2014/5/15
Y1 - 2014/5/15
N2 - BACKGROUND Large rearrangements in BRCA1 and BRCA2 occur in a small percentage (< 1%) of patients tested for hereditary breast (BC) and ovarian cancer. It is unclear what factors predict BRACAnalysis Large Rearrangement Test (BART) positivity. METHODS Data from 6 centers were included in this analysis. Individuals with negative Comprehensive BRACAnalysis tested for BART were included. RESULTS From 1300 individuals, 42 (3.2%) were BART positivity. Factors positively associated with BART positivity were Myriad score, first-degree relatives with BC, infiltrating BC with ductal carcinoma in situ, younger age at BC diagnosis, estrogen receptor-negative BC for both the first and second BC, and Latin American/Caribbean ethnicity. Presence of unilateral BC was inversely associated with BART positivity. Several analyses were performed on the variables available to find the model that best predicts for BART positivity. The BART predictive model, including first BC, ovarian cancer, primary maternal ancestry being Latin America/Caribbean, number of first-degree relatives with BC of 1 or more versus 0, and family history of prostate and pancreatic cancer, had good predictive ability with an area under the curve of 0.77. CONCLUSIONS Several factors are significantly associated with BART positivity. Among them we have found that Latin American/Caribbean ancestry, Myriad score, first degree relatives with BC, younger age at BC diagnosis, estrogen receptor-negative status of BC, and infiltrating ductal carcinoma with ductal carcinoma in situ features are significantly associated with BART positivity. A BART predictive model may help in a clinical setting.
AB - BACKGROUND Large rearrangements in BRCA1 and BRCA2 occur in a small percentage (< 1%) of patients tested for hereditary breast (BC) and ovarian cancer. It is unclear what factors predict BRACAnalysis Large Rearrangement Test (BART) positivity. METHODS Data from 6 centers were included in this analysis. Individuals with negative Comprehensive BRACAnalysis tested for BART were included. RESULTS From 1300 individuals, 42 (3.2%) were BART positivity. Factors positively associated with BART positivity were Myriad score, first-degree relatives with BC, infiltrating BC with ductal carcinoma in situ, younger age at BC diagnosis, estrogen receptor-negative BC for both the first and second BC, and Latin American/Caribbean ethnicity. Presence of unilateral BC was inversely associated with BART positivity. Several analyses were performed on the variables available to find the model that best predicts for BART positivity. The BART predictive model, including first BC, ovarian cancer, primary maternal ancestry being Latin America/Caribbean, number of first-degree relatives with BC of 1 or more versus 0, and family history of prostate and pancreatic cancer, had good predictive ability with an area under the curve of 0.77. CONCLUSIONS Several factors are significantly associated with BART positivity. Among them we have found that Latin American/Caribbean ancestry, Myriad score, first degree relatives with BC, younger age at BC diagnosis, estrogen receptor-negative status of BC, and infiltrating ductal carcinoma with ductal carcinoma in situ features are significantly associated with BART positivity. A BART predictive model may help in a clinical setting.
KW - BART
KW - BRCA1
KW - BRCA2
KW - breast cancer
KW - breast cancer rearrangement mutations
KW - mutations
UR - http://www.scopus.com/inward/record.url?scp=84899991774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899991774&partnerID=8YFLogxK
U2 - 10.1002/cncr.28577
DO - 10.1002/cncr.28577
M3 - Article
C2 - 24522996
AN - SCOPUS:84899991774
SN - 0008-543X
VL - 120
SP - 1557
EP - 1564
JO - Cancer
JF - Cancer
IS - 10
ER -